p53 TUMOUR SUPPRESSOR
WHY IT MATTERS IN CANCER

p53 is a protein — a transcription factor — produced by the TP53 gene on chromosome 17. Under normal conditions, p53 levels in cells are low. But when DNA is damaged by radiation, toxins, oncogene activation, or replication errors, p53 levels rise rapidly and it orchestrates one of three responses: repair the damage, halt cell division until repair is complete, or trigger programmed cell death (apoptosis) if the damage is irreparable.

“p53 is rightly called the guardian of the genome — it is the cell's last line of defence against becoming cancerous, and its loss removes the most powerful brake on tumour development.”

• The Three Responses p53 Coordinates

  When DNA damage is detected, p53 activates: (1) DNA repair genes — giving the cell time to fix the damage; (2) cell cycle arrest — pausing replication at G1 or G2 checkpoints until repair completes; (3) apoptosis — if damage is too severe to repair, p53 activates the intrinsic cell death programme, eliminating the dangerous cell before it can pass mutations to daughter cells.

• What Happens When p53 Is Lost

  With p53 inactivated by mutation, cells accumulate DNA damage without a coordinated repair or death response. Damaged cells divide, passing their mutations to daughter cells. This allows the progressive accumulation of oncogenic mutations — the hallmark of cancer progression. Crucially, p53 loss also impairs the response to chemotherapy and radiotherapy, both of which kill cells partly by inducing the p53-mediated apoptosis pathway.

The following figures illustrate why p53 is described as the most important tumour suppressor in human oncology.

• >50%Of all human cancers carry TP53 mutationsNo other gene is as frequently mutated across all cancer types — p53 dysfunction is the most universal molecular event in oncology.
• >70%TP53 mutation rate in HNSCC and ovarian cancerThe cancers with the highest p53 mutation rates — and the strongest rationale for Gendicine p53 restoration therapy.
• ~20,000Published studies on p53 in PubMedp53 is the most studied protein in cancer biology — more research has been published on TP53 than on any other single gene in oncology.
• 1979Year p53 was first identifiedDiscovered simultaneously by David Lane (UK) and Arnold Levine (US) — p53's tumour suppressor role was established a decade later in 1989.

TP53 mutation frequency varies by tumour type — the cancers with the highest rates represent the strongest biological targets for p53 restoration therapy.

p53 loss is not always caused by mutation of the TP53 gene itself — several distinct mechanisms can disable p53 function while leaving the TP53 sequence intact.

1. 1

   TP53 Point Mutation

   The most common mechanism — a single base change in the TP53 gene produces a structurally altered p53 protein that cannot bind DNA and activate target genes. Gain-of-function mutations add oncogenic properties on top of p53 loss.

2. 2

   TP53 Deletion

   Loss of one or both copies of chromosome 17p deletes the TP53 locus entirely. Homozygous deletion results in complete absence of p53 protein — seen most commonly in haematologic malignancies and some solid tumours.

3. 3

   MDM2 Overexpression

   MDM2 is the primary negative regulator of p53 — it binds p53, targets it for ubiquitin-mediated proteasomal degradation, and exports it from the nucleus. MDM2 amplification or overexpression effectively neutralises wild-type p53 without any TP53 mutation — seen in ~7% of all cancers.

4. 4

   Viral Oncoprotein Binding

   HPV E6 protein binds p53 and recruits an E3 ubiquitin ligase (UBR4) to degrade it — the primary mechanism of p53 inactivation in HPV-positive oropharyngeal and cervical cancer. Similarly, HBV HBx protein sequesters and degrades p53.

5. 5

   Epigenetic Silencing

   TP53 promoter hypermethylation is a rare but recognised p53 silencing mechanism in a subset of cancers — epigenetically eliminating p53 expression without genomic mutation.

A common question is: if the patient's own TP53 gene is mutated, how does Gendicine help? The answer lies in the nature of adenoviral gene delivery and the independence of the delivered gene from the endogenous mutant allele.

• Gendicine Delivers a New, Functional Gene — Not a Repair

  Gendicine does not repair the mutant TP53 gene. Instead, it delivers a completely new copy of wild-type p53 cDNA into tumour cells via the adenoviral vector. This new copy is expressed independently of the mutant endogenous allele — essentially adding a functional p53 protein to cells that previously had none.

• Why Even MDM2-Overexpressing Tumours May Respond

  When Gendicine delivers wild-type p53 in high concentrations, the resulting p53 protein levels can overcome partial MDM2-mediated degradation — saturating the MDM2 regulatory system and achieving net p53 activity above the apoptotic threshold. This is the rationale for its use even in tumours with intact TP53 sequences but upstream pathway disruption.

• The Bystander Effect: Beyond the Injected Tumour

  Adenoviral infection of tumour cells triggers an immune response that includes cytokine release and local inflammation. This creates an immunostimulatory microenvironment — and p53-expressing cells undergoing apoptosis release danger signals that can activate dendritic cells against tumour neoantigens, creating a limited vaccine-like effect analogous to the abscopal mechanism seen with cryoablation.

Continue exploring Gendicine — from cancer-specific clinical evidence to access and navigation.

Frequently Asked Questions

Common questions from patients trying to understand p53 and its relevance to their cancer.